title: Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus.
abstract: We studied the prognostic significance of antiphospholipid antibodies for recurrence of venous thromboembolism (VTE), in 71 patients admitted for acute VTE (deep-vein thrombosis or pulmonary embolism) in a single internal medicine unit. Lupus anticoagulant (LA), antibodies directed against beta 2-glycoprotein I (beta 2GPI) and antibodies against both beta 2GPI and a mixture of phospholipids (cardiolipin, phosphatidylserine and phosphatidic acid) (APAs) were measured. The patients were followed-up (mean 4.9 years) to determine the time to the next VTE. We found LA in nine patients, anti-beta 2GPI antibodies in seven patients and APAs in six patients. The cumulative risk of recurring VTE was higher in patients with beta 2GPI-binding antibodies (hazard ratio 12.6, 95% CI 1.5-104.9; p = 0.0029). The risk associated with APAs was 11.5 (95% CI 1.3-98.9; p = 0.0049) and that for LA was 3.7 (95% CI 0.9-15.6; p = 0.055). The risk of VTE recurring was higher both in patients with antibodies directed against beta 2GPI, and in patients with antibodies directed against beta 2GPI and a mixture of phospholipids, than in patients without these antibodies.
authors.affiliation: Nancy University Hospital, France.
authors.forename: D G
authors.initials: DG
authors.lastname: Wahl
authors.forename: E
authors.initials: E
authors.lastname: De Maistre
authors.forename: F
authors.initials: F
authors.lastname: Guillemin
authors.forename: V
authors.initials: V
authors.lastname: Regnault
authors.forename: C
authors.initials: C
authors.lastname: Perret-Guillaume
authors.forename: T
authors.initials: T
authors.lastname: Lecompte
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000276:immunology; D012008:Recurrence; D012044:Regression Analysis; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology* / Q000276:immunology; D053482:beta 2-Glycoprotein I
chemical_list: D000906:Antibodies; D017152:Antibodies, Antiphospholipid; D015415:Biomarkers; D006023:Glycoproteins; D010743:Phospholipids; D053482:beta 2-Glycoprotein I